WINTON GROUP Ltd Buys New Stake in Adaptive Biotechnologies Corporation $ADPT

WINTON GROUP Ltd bought a new stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 49,700 shares of the company’s stock, valued at approximately $807,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of ADPT. AQR Capital Management LLC grew its holdings in shares of Adaptive Biotechnologies by 45.8% in the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock valued at $2,265,000 after purchasing an additional 97,444 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Adaptive Biotechnologies by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock valued at $511,000 after purchasing an additional 2,914 shares in the last quarter. Caxton Associates LLP purchased a new position in shares of Adaptive Biotechnologies in the first quarter valued at $93,000. New York State Common Retirement Fund grew its holdings in shares of Adaptive Biotechnologies by 39.2% in the second quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock valued at $551,000 after purchasing an additional 13,300 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Adaptive Biotechnologies by 728.8% in the second quarter. Arrowstreet Capital Limited Partnership now owns 379,120 shares of the company’s stock valued at $4,417,000 after purchasing an additional 333,379 shares in the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on ADPT shares. Morgan Stanley cut their target price on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. BTIG Research reissued a “buy” rating and issued a $22.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday, May 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Monday, April 20th. Wall Street Zen lowered shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Guggenheim reaffirmed a “buy” rating and set a $21.00 price objective on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $19.57.

Adaptive Biotechnologies Stock Down 1.7%

NASDAQ ADPT opened at $17.07 on Thursday. The company has a fifty day moving average of $14.41 and a two-hundred day moving average of $15.67. The firm has a market capitalization of $2.73 billion, a price-to-earnings ratio of -51.73 and a beta of 2.15. Adaptive Biotechnologies Corporation has a 52 week low of $9.90 and a 52 week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. The company had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative net margin of 16.82% and a negative return on equity of 40.06%. Adaptive Biotechnologies’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.20) earnings per share. Equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 EPS for the current year.

Insiders Place Their Bets

In other news, CFO Kyle Piskel sold 3,115 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were sold at an average price of $13.04, for a total value of $40,619.60. Following the transaction, the chief financial officer directly owned 256,725 shares in the company, valued at approximately $3,347,694. This represents a 1.20% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Susan Bobulsky sold 11,000 shares of the company’s stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $18.00, for a total transaction of $198,000.00. Following the completion of the transaction, the insider owned 416,775 shares in the company, valued at approximately $7,501,950. The trade was a 2.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 535,714 shares of company stock worth $7,756,708. 5.70% of the stock is currently owned by company insiders.

Adaptive Biotechnologies Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.